Supernus Pharmaceuticals, Inc. (SUPN) — 10-Q Filings
All 10-Q filings from Supernus Pharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Supernus Swings to Loss Amid Sage Acquisition, ZURZUVAE Launch
— Nov 6, 2025 Risk: high
SUPERNUS PHARMACEUTICALS, INC. reported a significant net loss of $45.1 million for the three months ended September 30, 2025, a sharp decline from a net income -
Supernus Q2 Revenue Jumps 21%, Net Income Dips Amid Rising Costs
— Aug 5, 2025 Risk: medium
SUPERNUS PHARMACEUTICALS, INC. reported a significant increase in total revenues for the three and six months ended June 30, 2025. Total revenues for the second -
Supernus Pharmaceuticals Files Q1 2025 10-Q
— May 6, 2025 Risk: medium
Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results for the first quarter of 2025. Ke -
Supernus Pharmaceuticals Files Q3 2024 10-Q
— Nov 4, 2024 Risk: medium
Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported royalty, license, and other revenue for the third q -
Supernus Pharma Q2 2024 10-Q Filed
— Aug 6, 2024 Risk: medium
Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported royalty, license, and other revenue for the second quart -
Supernus Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: medium
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Revenue for the three months ended March 31, 2024, was $178.5
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX